ArticleThe oncologist2025
Advancing breast cancer rehabilitation: a novel tool for assessing physical morbidity risk.
Article in The oncologist, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Beyond surgical risk: Multidimensional predictors of postoperative arm morbidity after breast cancer treatment.Breast (Edinburgh, Scotland) · 2026Article
- Article
- Effect of home exercise on prevention and treatment of lymphedema in breast cancer patients.Frontiers in oncology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
purposeThis study presents the development process of the Arm Morbidity following Breast Cancer Treatments (ARM-BCT) tool. MATERIALS AND
methodsA historical prospective study was conducted across five medical centers from 2020 to 2023. Medical information and a questionnaire covering morbidities, lifestyle, emotional state, and functioning were collected. Regression models analyzed 22 risk factors for chronic pain, lymphedema, functional limitations, and decreased range of motion. Significant factors were included in the ARM-BCT tool.
resultsSeventeen significant risk factors were identified, including mastectomy (B = 2.073, CI, 7.403-5.366), axillary lymph node dissection (B = 0.194, CI, 0.988-1.036), breast reconstruction (B = 17.300, CI, 7.105-27.495), advanced stage (B = 0.498, CI, 1.044-2.594), chemotherapy (B = 1.326, CI, 0.870-3.673), BMI (B = 0.092, CI, 1.033-1.163), anxiety (B = 0.177, CI, 1.859-3.079), low physical activity levels (B = -0.059, CI, 0.190-0.001), specific comorbidities (B = -1.491, CI, 2.706-0.277), age (B = 0.035, OR = 1.036, CI, 1.002-1.071), and radiation therapy (B = 0.385, CI, 0.380-2.056), etc. The tool's development involved robust statistical modeling to determine the weight of each factor, evaluate model quality, and establish a clinically relevant cutoff point.
conclusionThis article describes the development process of the ARM-BCT tool, designed to assess the risk of physical morbidity following breast cancer treatment. The tool incorporates 17 statistically significant risk and protective factors into a scoring scale ranging from 1 to 20. Risk is categorized as low (< 6) or high (> 7), enabling targeted recommendations for rehabilitation timing and necessity. While validation studies evaluating its clinical effectiveness are underway and will be presented in future publications, the ARM-BCT tool shows promise in enhancing recovery outcomes through early intervention.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.